| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Tubulin
Vinflunine ditartrate targets tubulin, binding to tubulin and inhibiting tubulin assembly and disrupting microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis. As a member of the Vinca alkaloids family, it shares a similar mechanism of action with other vinca alkaloids such as vincristine and vinblastine, but with a distinct fluorinated structure. |
|---|---|
| ln Vitro |
Vinorelbine causes tubulin to aggregate into spirals and paracrystals, which prevents the formation of microtubules.[1]
Vinorelbine shows potent antiproliferative properties against various tumor cells, such as human melanoma, breast cancer, non-small-cell lung cancer, etc. [2][3][4] In vitro, vinflunine ditartrate demonstrates anti-angiogenic, vascular-disrupting, and anti-metastatic activities. As a microtubule inhibitor, it disrupts the mitotic spindle and induces cell cycle arrest in mitosis. Specific IC50 values for inhibition of tubulin assembly or cell proliferation are not detailed in the available sources. The compound has been used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast. |
| ln Vivo |
Vinorelbine also exhibits antitumor activity in vivo when applied topically to a number of human tumor xenografts.[5]
Vinflunine ditartrate has been evaluated in vivo for the treatment of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and breast cancer. It has shown anti-angiogenic, vascular-disrupting, and anti-metastatic activities in preclinical models. The compound is approved for clinical use in some countries for the treatment of advanced or metastatic urothelial cancer. Specific animal model data are not detailed in the available sources. |
| Enzyme Assay |
Purified tubulin (17 μM) is polymerized into microtubules using sea urchin (Strongylocentrotus purpuratus) axonemes as seeds for assembly initiation in 75 mM PIPES, 1.8 mM MgCl2, 1.0 mM EGTA, and 1.5 mM GTP, either in the absence or presence of a range of flunine concentrations (35 minutes; 37 °C). Centrifugation (150,000 × g; 1 hour; 35 °C) is used to separate polymerized microtubules from unpolymerized tubulin after incubation. After aspirating the supernatant and putting the sedimented microtubules in assembly buffer for two hours on ice to depolymerize them, the protein content is calculated.
The tubulin binding assay for vinflunine involves incubating the compound with purified tubulin in a polymerization buffer containing GTP. Tubulin polymerization is monitored by turbidity at 350 nm using a spectrophotometer. The compound's ability to inhibit tubulin assembly is assessed by measuring the decrease in absorbance over time. Alternatively, a competitive binding assay using [³H]-vinblastine can be performed to determine the binding affinity of vinflunine for the vinca alkaloid binding site on tubulin. |
| Cell Assay |
Vinflunine's effects on the proliferation of L1210 cells are assessed using a common growth inhibition test. After being exposed to various concentrations of test compounds for 48 hours, exponentially growing L1210 cells (1.5 × 105 cells/well) in a 24-well plate are counted using an electronic particle counter that uses linear interpolation between data points to determine the number of cells.
To evaluate the cellular activity of vinflunine, cancer cell lines (such as bladder cancer or lung cancer cells) are seeded in 96-well plates and treated with varying concentrations of the compound. After 48-72 hours of incubation, cell viability is measured using an MTT or CellTiter-Glo assay. The GI50 (concentration causing 50% growth inhibition) is calculated. Cell cycle analysis is performed by flow cytometry to assess mitotic arrest. Apoptosis induction is evaluated by measuring caspase activity or using annexin V-FITC staining. |
| Animal Protocol |
Dissolved in in a saline solution (0.9% NaCl); 20 mg/kg; i.v. injectionLS174T tumor cells are injected into the spleen of BALB/C nude mice.
The in vivo efficacy of vinflunine is evaluated in xenograft models using human cancer cell lines implanted subcutaneously into immunodeficient mice. Vinflunine is administered intravenously at various doses, typically on a weekly schedule. Tumor volume and body weight are measured twice weekly. Antitumor activity is expressed as tumor growth inhibition (TGI) percentage relative to the control group. The compound's anti-angiogenic and vascular-disrupting effects can be assessed by immunohistochemical analysis of tumor vasculature. |
| ADME/Pharmacokinetics |
Vinflunine is administered intravenously and has a pharmacokinetic profile characterized by a long terminal half-life and extensive tissue distribution. It is metabolized in the liver and excreted primarily via the biliary route. Specific pharmacokinetic parameters (e.g., Cmax, Tmax, AUC) are not detailed in the available sources. The compound has a molecular weight of 1117.1 g/mol and is formulated as a concentrated injection.
|
| Toxicity/Toxicokinetics |
Vinflunine is generally well-tolerated, with common adverse effects including neutropenia, anemia, fatigue, and constipation. As a vinca alkaloid, it carries a risk of neurotoxicity and myelosuppression. The compound is approved for clinical use in some countries for the treatment of advanced or metastatic urothelial cancer. Specific toxicity data from preclinical studies are not detailed in the available sources.
|
| References | |
| Additional Infomation |
Vinpocetine tartrate is the tartrate salt of vinorelbine, a semi-synthetic difluorinated derivative of the vinorelbine alkaloid, which possesses potential antimitotic and antitumor activities. Vinpocetine binds to tubulin, inhibiting tubulin assembly and disrupting microtubule assembly kinetics. This leads to cell cycle arrest at the mitotic phase and induces apoptosis.
See also: Vinpocetine tartrate (note moved to). Vinflunine ditartrate is also known as BMS 710485 and 4'-Deoxy-20',20'-difluoro-5'-norvincaleukoblastine ditartrate. It is a fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. The compound exhibits anti-angiogenic, vascular-disrupting, and anti-metastatic properties and is used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and breast cancer. |
| Molecular Formula |
C53H66F2N4O20
|
|
|---|---|---|
| Molecular Weight |
1079.11
|
|
| Exact Mass |
1116.423
|
|
| Elemental Analysis |
C, 66.16; H, 6.66; F, 4.65; N, 6.86; O, 15.67
|
|
| CAS # |
194468-36-5
|
|
| Related CAS # |
194468-36-5 (ditartrate);162652-95-1;
|
|
| PubChem CID |
46174139
|
|
| Appearance |
White to off-white solid powder
|
|
| Hydrogen Bond Donor Count |
10
|
|
| Hydrogen Bond Acceptor Count |
25
|
|
| Rotatable Bond Count |
16
|
|
| Heavy Atom Count |
79
|
|
| Complexity |
1850
|
|
| Defined Atom Stereocenter Count |
13
|
|
| SMILES |
OC([C@@H]([C@H](C(=O)O)O)O)=O.OC([C@@H]([C@H](C(=O)O)O)O)=O.CC([C@H]1CN2C[C@@H](C[C@@](C3=C(OC)C=C4C([C@]56CCN7CC=C[C@@]([C@@H]57)(CC)[C@@H](OC(=O)C)[C@](O)(C(OC)=O)[C@@H]6N4C)=C3)(C(OC)=O)C3NC4=CC=CC=C4C=3C2)C1)(F)F
|
|
| InChi Key |
YIHUEPHBPPAAHH-IIQAEXPMSA-N
|
|
| InChi Code |
InChI=1S/C45H54F2N4O8.2C4H6O6/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44;2*5-1(3(7)8)2(6)4(9)10/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t26-,27+,36-,37+,38+,42+,43+,44-,45-;2*1-,2-/m011/s1
|
|
| Chemical Name |
(2R,3R)-2,3-dihydroxybutanedioic acid;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(12S,14S,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9267 mL | 4.6334 mL | 9.2669 mL | |
| 5 mM | 0.1853 mL | 0.9267 mL | 1.8534 mL | |
| 10 mM | 0.0927 mL | 0.4633 mL | 0.9267 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA